Oversight of 340B, as Measured by Audits/Audit Findings, Is Woefully Lagging, New Analysis Finds

First off, there aren’t capital letters big enough to express the CONGRATS I’d like to pass along to Adam Fein, whose Drug Channels Institute has been acquired by HMP Global.

Thanks to everyone who weighed in on the future of Cost Curve yesterday. I’m keeping the survey open for another day, so if you haven’t clicked over, I’d be appreciative

As is tradition, Merck is out as the first company to talk about 2023 list- and net-price changes across its portfolio. The company dropped its annual Pricing Action Transparency Report